Financial Data and Key Metrics Changes - Fiscal first quarter revenue was $10.8 million compared to $4 million for the prior year period, primarily driven by $7.4 million in revenue from the sale of a built-to-suit property [12] - The company reported a net loss of $7.9 million for the quarter versus net income of $3 million a year ago, mainly due to unrealized losses on investments [13] - Adjusted EBITDA for the quarter was a loss of $500,000 compared to a gain of $1.3 million in the prior year period [13] - Fee-paying assets under management (AUM) grew 9% year over year to approximately $594 million, or 10% on a pro forma basis to approximately $601 million [4][12] Business Line Data and Key Metrics Changes - Monomoy BTS sold its second built-to-suit development property for over $7 million, generating a gain of over $500,000 [6] - Investment management and property management fees at Monomoy CRE increased 12% over the prior year period, driven by growth in fee-paying AUM and rental income [8] - GECC raised approximately $28 million in equity proceeds, including a $15 million private placement and $13 million through its At the Market Equity Program [8] Market Data and Key Metrics Changes - The REIT deployed over $13 million to acquire seven new properties at attractive cap rates [8] - GECC doubled its borrowing capacity under its revolver to $50 million, reducing the interest rate by 50 basis points [9] Company Strategy and Development Direction - The company aims to expand its platform, grow assets under management, and enhance profitability [4] - A transformative partnership with Kennedy Lewis Investment Management was established, committing up to $150 million in leverageable capital to accelerate real estate platform expansion [5] - The company is focused on growing fee-paying AUM and scaling its credit and real estate platforms [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction of the business and the ability to leverage fixed costs for growth [17][18] - Despite setbacks from First Branch's bankruptcy, the company believes it is in a strong position with ample deployable cash and a solid balance sheet [10][11] Other Important Information - The company ended the quarter with approximately $53.5 million in cash, providing flexibility for growth initiatives [11] - The stock repurchase program was expanded by $5 million to a total of $25 million, with 5.6 million shares repurchased for $10.9 million [11] Q&A Session Summary Question: Current growth trajectory and expense structure - Management indicated that the bulk of fixed costs are in place, and the focus is now on growth, particularly in real estate and BDC [17][18] Question: Information on Monomoy REIT - Management acknowledged the limited public information on Monomoy REIT, which focuses on industrial outside storage and has over 150 buildings [20][21] - The REIT has built a built-to-suit business and aims for potential public listing in the future [21][22]

Core Insights - The chip maker has been actively raising capital from various sources [1] Group 1 - The company is exploring multiple avenues for capital generation [1]

Core Points - Radiopharm Theranostics Limited has successfully raised approximately A$35 million through a private placement of new shares at A$0.03 per share, with significant participation from institutional investors including Lantheus Holdings, Inc. [1][5][6] - The company will also conduct a Share Purchase Plan (SPP) to raise an additional A$5 million for existing eligible shareholders, maintaining the same terms as the placement [3][6]. Placement Details - The placement involves the issuance of approximately 1,167 million new fully paid ordinary shares, with Lantheus investing A$7.6 million, increasing its shareholding to 14.5% [5][6]. - Each placement subscriber will receive one free attaching option for every share subscribed, with an exercise price of A$0.039 and an expiration date of October 31, 2027 [2][10]. Use of Funds - The funds raised will be allocated as follows: A$6 million for drug manufacturing, A$34 million for clinical trials, and A$19 million for administration and working capital, extending the funding runway into 2027 [4][7][6]. Shareholder Approval - The second tranche of the placement, amounting to A$22.5 million, will require shareholder approval at an upcoming Extraordinary General Meeting (EGM) anticipated in early December 2025 [9][10].

Core Viewpoint - GBM Resources has successfully raised A$39.85 million (approximately $26.14 million) through an institutional placement to accelerate exploration and development in its Drummond Basin gold portfolio in Queensland [1][3]. Fundraising Details - The placement involves issuing approximately 752 million new shares at A$0.053 each, which represents a 3.6% discount to GBM's last closing price and a 4.7% discount to its ten-day volume-weighted average price [2]. - Canaccord Genuity (Australia) acted as the lead manager and bookrunner, with Argonaut Securities co-leading the placement [2]. Use of Proceeds - Proceeds from the placement, along with existing cash reserves, will be allocated to enhance exploration and development activities at GBM's 100%-owned Drummond Basin assets, which contain mineral resources of around 1.84 million ounces [3]. - The funds will also support business development initiatives and general working capital [3]. Capital Raising Structure - The capital raising will occur in two tranches: the first tranche involves 600 million shares issued under existing placement capacity, while the second tranche consists of 151.9 million shares to Wise Walkers, pending shareholder approval [4]. - GBM CEO Daniel Hastings expressed satisfaction with the positive response to the placement and emphasized the importance of strengthening the balance sheet to support growth in existing resources and systematic exploration [4].

Group 1 - Alibaba Group's American depositary shares (ADSes) rose nearly 3% following a successful capital-raising round, outperforming the S&P 500 index's gain of 0.2% [1] - The company completed a flotation of approximately $3.2 billion in zero coupon convertible senior notes, with purchasers being "certain non-U.S. persons" [2] - The notes can be converted into ADSes at an initial rate of nearly 5.18 per $1,000 principal amount, with a conversion price of $193.15 per ADS, representing a more than 31% premium to the price of its Hong Kong-listed shares [3] Group 2 - Alibaba plans to use the proceeds from the note sales for general corporate purposes, specifically to enhance its cloud infrastructure and international operations [4] - The capital-raising method is viewed positively by investors as it is not expected to significantly dilute existing shareholders or burden the balance sheet, with a market cap of nearly $397 billion and a debt of $32 billion [5]

For personal use only WAGNERS INVESTOR PRESENTATION SEPTEMBER 2025 Executive Summary | | ▪ | Wagners Holding Company Limited ("WGN" or the "Company") is undertaking a capital raising of approximately A$30 million by way of an institutional placement | | --- | --- | --- | | | | ("Placement") of new fully paid ordinary shares in the Company ("New Shares"), the ("Offer"). | | Transaction Overview | ▪ | The funds received under the Placement will be used to pursue growth strategies in Construction Materials and ...

Core Insights - American Trust Investment Services, Inc. (ATIS) acted as the exclusive placement agent for Nova LifeStyle, Inc. in a follow-on public offering, raising gross proceeds of $9 million through the sale of 9,836,054 shares and 19,672,108 warrants priced at $0.915 each [1][2] Group 1: Transaction Details - The offering included each share of common stock issued with two five-year warrants, exercisable at $1.098, which is 120% of the public offering price [2] - The net proceeds from the offering will be utilized for working capital, marketing initiatives, repayment of certain short-term debt, and general corporate purposes [3] Group 2: Company Background - Nova LifeStyle is a U.S.-based designer and marketer of modern lifestyle furniture, operating under brands such as Nova Brands and Diamond Sofa [3] - ATIS is recognized for its strategic approach in providing customized capital markets solutions to high-growth companies, with a focus on small and mid-cap markets [4][5]

Capital Raising and Financial Position - Liontown is undertaking a capital raising of approximately A$266 million to strengthen its balance sheet and provide a liquidity buffer[38, 42] - The pro forma cash balance after the capital raising is expected to be approximately A$422 million before transaction costs[42, 99] - The National Reconstruction Fund Corporation (NRFC) is investing A$50 million in Liontown as part of the capital raising at A$0.73 per share[42, 105] Operational Performance and Future Plans - In FY25, Liontown produced over 320,000 wmt of concentrate at 5.2% Li2O with 8% moisture, equivalent to over 294,000 dmt[38, 53] - Underground production stoping has commenced on schedule[38] - FY26 is expected to be a transition year for Kathleen Valley as underground production ramps up, with 100% underground production planned by Q3 FY26[42, 60] - A lithia recovery target of 70% by Q3 FY26 remains unchanged[42, 60] Financial Metrics and Guidance - FY25 revenue was A$301 million with an average realised price of A$1,061 per dmt (CIF) for ~SC5[53] - H2 FY25 unit operating cost was A$802 per dmt sold (FOB), and AISC was A$1,081 per dmt sold (FOB)[53] - FY26 concentrate production is guided at 365,000 - 450,000 dmt, with All in Sustaining Costs of A$1,060 - A$1,295 per dmt sold and Unit Operating Costs of A$855 - A$1,045 per dmt sold[61]

Financial Data and Key Metrics Changes - The company reported FFO as adjusted of $0.46 per share and AFFO of $0.44 per share, with total portfolio same store growth of 3.5% [19] - CCRC business reported same store growth of 8.6%, driven by rate growth of 5% and higher entrance fee sales [19] - Outpatient medical segment achieved 85% tenant retention, with a positive rent mark to market of 6% and same store cash NOI growth of 3.9% [20] Business Line Data and Key Metrics Changes - Outpatient medical segment saw same store growth of 3.9%, with over 1,000,000 square feet of leases executed, including approximately 200,000 square feet of new leasing [20] - CCRC portfolio generated approximately $200,000,000 of annual NOI, which is 50% higher than in 2019 before the pandemic [14] - Lab R&D business is beginning to see positive indicators, with new supply quickly going to zero [11] Market Data and Key Metrics Changes - The company has significant concentration in markets like Dallas, Houston, Nashville, Atlanta, Phoenix, and Denver, which are expected to drive growth [10] - Recent broker reports indicated over 4,000,000 square feet of inventory being removed from the supply pipeline in the lab sector [12] - The occupancy in the outpatient medical portfolio remains strong at 91-92% [48] Company Strategy and Development Direction - The company is focusing on internalizing property management to enhance tenant relationships and operational efficiency [8] - A strategic plan is being implemented to enhance operating procedures and elevate service standards [18] - The company is optimistic about the regulatory environment, particularly the proposed rule from CMS that would allow more procedures to be performed in outpatient settings [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution from the team and the diversified portfolio, despite challenges in the lab sector [24] - The political and regulatory environment is improving, with favorable changes in drug pricing and tax treatment for research and manufacturing [7][10] - Management noted that the capital markets have shown signs of improvement, which could benefit tenants seeking to raise capital [40][56] Other Important Information - The company completed an enterprise-wide technology upgrade to improve data integration and productivity [5] - The internalization of property management is expected to generate profit and improve tenant satisfaction [9] - The company has nearly $2,300,000,000 of liquidity and ended the quarter with a net debt to adjusted EBITDA of 5.2 times [22] Q&A Session Summary Question: Can you break down the occupancy decline in the lab segment? - Management indicated that the occupancy decline was due to lease expirations, tenant migration, and some tenants unable to raise capital [28][29] Question: What are the thoughts on capital allocation and balance sheet usage? - Management emphasized maintaining a strong balance sheet and being opportunistic with asset sales and buybacks [32][34] Question: How much impact do you expect from unsuccessful capital raises on occupancy? - Management acknowledged some headwinds for occupancy but noted positive signs in the capital markets that could improve the situation [40][42] Question: Can you provide insights on the development pipeline and capitalized interest? - Management stated that capitalized interest will trend down as projects come online, with ongoing entitlement processes for large projects [76] Question: What are the expectations for the CCRC occupancy? - Management noted that the sequential dip in occupancy is typical seasonality, with strong performance in independent living [78][80] Question: How does the company view the regulatory changes and their impact? - Management expressed optimism about regulatory changes, particularly the shift towards outpatient settings, which aligns with the company's focus [10][106]

Core Viewpoint - Quantum BioPharma Ltd. announces that Unbuzzd Wellness Inc. is raising up to US$5 million through a Regulation D 506(c) offering to support its expansion plans for the unbuzzd™ beverage, which accelerates alcohol metabolism and reduces hangover symptoms [1][2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on unbuzzd™ sales until reaching $250 million, after which the royalty rate drops to 3% [3] Product Details - Unbuzzd™ is a scientifically-backed beverage designed to help alcohol consumers process alcohol faster, restore mental clarity, and alleviate hangover symptoms [5][6] - Clinical trials show that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][13] - Participants reported significant improvements in alertness and reductions in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [13] Leadership and Strategy - John Duffy, CEO of Unbuzzd, emphasizes the commitment to providing a scientifically backed product to alcohol consumers and the importance of the capital raise for expansion [2] - Gerry David, Board Co-Chair, highlights that the capital raise will support company growth and position unbuzzd for a potential initial public offering [3]